Dentsply Sirona Inc (XRAY)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.83B
Last updated: Nov 17, 2026 at 11:06 AM ET
Dentsply Sirona Inc (XRAY) Stock Forecast
Analysts expect Dentsply Sirona (XRAY) to earn $1.33 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.51B. Of 17 analysts, 4 rate the stock Buy or Strong Buy, 12 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.76, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 24% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 11.8% |
| Buy | 2 | 11.8% |
| Hold | 12 | 70.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.9% |
- Consensus
- Hold
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 6.0% and revenue estimates rise 0.3%.
- Fiscal year ending Dec 31, 2026
- $1.33
- EPS consensus, revenue $3.51B
- Fiscal year ending Dec 31, 2027
- $1.25
- EPS consensus, revenue $3.52B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.33 | $1.22 to $1.46 | 16 | $3.51B | $3.48B to $3.55B | 15 |
| Dec 31, 2027 | $1.25 | $1.08 to $1.55 | 17 | $3.52B | $3.43B to $3.62B | 16 |
Quarterly Estimates
The EPS consensus falls from $0.31 for the quarter ending Dec 31, 2026 to $0.27 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.31 | $0.16 to $0.49 | 18 | $909.19M | $862.78M to $957.60M | 16 |
| Mar 31, 2027 | $0.27 | $0.23 to $0.31 | 11 | $860.80M | $832.00M to $891.20M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 13 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 5 |
| Fiscal year ending Dec 31, 2027 | 0 | 6 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 11.3% from $1.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.33 | $1.49 | $1.49 | $1.50 | $1.50 | -11.5% |
| Fiscal year ending Dec 31, 2027 | $1.25 | $1.48 | $1.50 | $1.52 | $1.52 | -17.8% |
| Quarter ending Mar 31, 2027 | $0.27 | $0.30 | $0.30 | $0.30 | $0.31 | -12.9% |
Frequently Asked Questions About XRAY
What is the XRAY stock forecast?
Consensus analyst estimates put Dentsply Sirona's EPS at $1.33 for the fiscal year ending Dec 31, 2026, on revenue of $3.51B. The consensus rating from 17 analysts is Hold.
How do analysts rate XRAY stock?
Of 17 analysts covering Dentsply Sirona, 2 rate it Strong Buy, 2 Buy, 12 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from XRAY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.33, with estimates from $1.22 to $1.46 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.25, with estimates from $1.08 to $1.55 from 17 analysts.
What revenue do analysts expect from Dentsply Sirona next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.51B, with estimates from $3.48B to $3.55B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.52B, with estimates from $3.43B to $3.62B.
How many analysts cover XRAY?
17 analysts rate Dentsply Sirona stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
XRAY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts